Joseph D Metzger

US Patent:

6410236, Jun 25, 2002

Filed:

Sep 1, 1999

Appl. No.:

09/387919

Inventors:

Joseph M. Metzger - Ann Arbor MI

Assignee:

The Regents of The University of Michigan - Ann Arbor MI

International Classification:

C12Q 168

US Classification:

435 6

Abstract:

The present invention relates to the overexpression of a calcium binding protein in cardiac myocytes in vivo and in vitro, and in particular, to the correction of diastolic dysfunction. Expression of the calcium binding protein parvalbumin in cardiac myocytes results in an increase in the rate of relaxation of the cardiac myocyte, in vivo and in vitro. The parvalbumin is expressed from an adenovirus vector, adeno-associated virus vector, or gutted adenovirus vector. The transfected in vivo and in vitro cardiac myocytes are also useful in drug screens.

US Patent:

7846426, Dec 7, 2010

Filed:

Feb 27, 2006

Appl. No.:

11/885304

Inventors:

Joseph M. Metzger - Ann Arbor MI, US
Dewayne Townsend - Ann Arbor MI, US
Soichiro Yasuda - Ann Arbor MI, US
Daniel E. Michele - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61K 31/77

US Classification:

424 7838, 435375

Abstract:

The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e. g. , poloxamer 188—P188) and methods of using the same for treating and preventing heart disease (e. g. , in subjects with muscular dystrophy) and for treating cells and tissue damage caused by ischemia and cell death (e. g. , for treating dystrophin-deficient cells (e. g. , myocytes)).

US Patent:

8557969, Oct 15, 2013

Filed:

Dec 1, 2005

Appl. No.:

11/792216

Inventors:

Joseph Metzger - Ann Arbor MI, US
Margaret Westfall - Ann Arbor MI, US
Sharlene Day - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI

International Classification:

C07H 21/02

US Classification:

536 231, 514 44 R

Abstract:

The present invention relates to cardiac performance, in particular to regulating cardiac performance via recombinant troponin I (TnI) protein and nucleic acids encoding recombinant TnI. The present invention provides nucleic acids encoding gain of function TnI proteins (e. g. , cTnlA164H), vectors containing such nucleic acids, host cells containing such vectors, transgenic animals carrying a gain of function TnI protein (e. g. , a cTnlA164H transgene), and therapeutic agents (e. g. , comprising recombinant TnI, TnI analogues, synthetic TnI, or the like) or agents for gene therapy of heart failure or disease for research and therapeutic uses.

US Patent:

8580245, Nov 12, 2013

Filed:

Oct 29, 2010

Appl. No.:

12/915352

Inventors:

Joseph M. Metzger - Ann Arbor MI, US
Dewayne Townsend - Ann Arbor MI, US
Soichiro Yasuda - Ann Arbor MI, US
Daniel E. Michele - Ann Arbor MI, US

Assignee:

The Regents of the University of Michigan - Ann Arbor MI

International Classification:

A61K 31/77

US Classification:

424 7838

Abstract:

The present invention relates to compositions and methods for treating and preventing heart disease. In particular, the present invention provides compositions comprising poloxamers (e. g. , poloxamer 188-P188) and methods of using the same for treating and preventing heart disease (e. g. , in subjects with muscular dystrophy) and for treating cells and tissue damage caused by ischemia and cell death (e. g. , for treating dystrophin-deficient cells (e. g. , myocytes)).